USD 268.00
In stock
Be the first to review this item
Akatinol Memantine (Acatinol Memantine, Memantinum) - a muscle relaxant central action. As a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, exerts a modulatory effect on the glutamatergic system. Adjusts ion transport, blocks calcium channels, normalizes membrane potential, improves the process of transmission of nerve impulses, improves cognitive processes, memory and learning ability, improves activities of daily living.
As a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, exerts a modulatory effect on the glutamatergic system. Adjusts ion transport, blocks calcium channels, normalizes membrane potential, improves the transmission of nerve impulses. Improves cognitive processes, increases the activities of daily living.
Testimony:
Contraindications:
Carefully:
Drug interactions:
In an application with drugs L-dopa, dopamine agonists, anticholinergics the last action can be strengthened. In an application with barbiturates, neuroleptics last action can be reduced. In a joint application may change (increase or decrease) the effect of dantrolene or baclofen, so drugs dosage should be adjusted individually. Avoid co-administration with amantadine, ketamine and deksametorfanom. Perhaps an increase in plasma levels of cimetidine, procainamide, kinidina, kinin and nicotine when taken with memantine. Perhaps the decline in the level of hydrochlorothiazide at simultaneous reception with memantine.
Suggested Use:
Akatinol Memantine Inside, during a meal. Dosage is determined individually. Initiate therapy with the recommended destination minimally effective doses.
Adults with dementia during the 1st week of treatment - 5 mg / day, 2nd week - at a dose of 10 mg / day, the 3rd week - at a dose of 15-20 mg / day. If necessary, may further increase a weekly dose of 10 mg to achieve a daily dose - 30 mg.
The optimal dose is achieved gradually by increasing the dose every week.
Special instructions:
In patients with Alzheimer's disease at the stage of moderate to severe dementia usually impair the ability to drive vehicles and management of complex mechanisms. Furthermore, memantine may cause a change in the reaction rate, so patients receiving treatment on an outpatient basis, you should be particularly careful when driving or operating machinery.
Packaging:
Storage:
Important notice- the outer box design may vary before prior notice!